Premium
Lack of Interaction of Gabapentin with Carbamazepine or Valproate
Author(s) -
Radulovic Louis L.,
Wilder B. J.,
Leppik Ilo E.,
Bockbrader Howard N.,
Chang Tsun,
Posvar Edward L.,
Sedman Allen J.,
Uthman Basim M.,
Erdman Gary R.
Publication year - 1994
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.1994.tb02926.x
Subject(s) - carbamazepine , pharmacokinetics , anticonvulsant , gabapentin , pharmacology , valproic acid , drug interaction , epilepsy , chemistry , medicine , alternative medicine , pathology , psychiatry
Summary: Gabapentin (GBP) studies were conducted in patients with epilepsy receiving carbamazepine (CBZ, n= 12) or valproate (VPA, n = 14) monotherapy. The effects of GBP coadministration on steady‐state CBZ or VPA concentrations and of these antiepileptic drugs (AEDs) on GBP pharmacokinetics were investigated. GBP (400 mg) was coadministered every 8 h for 3% days with CBZ or for 5 1/3 days with VPA. GBP was well tolerated. Mean steady‐state plasma CBZ/CBZ‐10, ll‐epoxide (CBZ‐E) and serum VPA concentrations before, during, and after GBP administration were not significantly different. Mean steady‐state GBP pharmacokinetic parameters during CBZ or VPA coadministration were similar to steady‐state parameters reported in healthy subjects. Thus, no pharmacokinetic interaction exists between CBZ or VPA and GBP. No dosage adjustment is necessary when GBP and CBZ or VPA are coadministered.